CML (Chronic Myelogenous Leukemia) Clinical Trial
Official title:
Validation Value of the Questionnaire to Assess Health-related Quality of Life in Patients With CML
Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.
1. Above 18 years of age. 2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML). 3. Written informed consent. 4. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
| Completed |
NCT02161978 -
Vascular Dysfunction and Antiangiogenic Therapy
|
||
| Completed |
NCT00467961 -
Stem Cell Transplantation for Patients With Cancers of the Blood
|
Phase 2 |